Other Events ·
Nasdaq confirms Alaunos Therapeutics regained compliance with $2.5M stockholders' equity requirement
TCRTAlaunos Therapeutics, Inc.
The Nasdaq Stock Market notified Alaunos Therapeutics of non-compliance with the $2,500,000 minimum stockholders' equity listing standard in April 2026 and issued a delisting notice on October 5, 2026. Following a private placement financing completed on October 14, 2026, Nasdaq confirmed on October 22 that the company has regained compliance with the Stockholders’ Equity Requirement. Consequently, Nasdaq closed the matter and cancelled the scheduled hearing before the Nasdaq Hearings Panel for November 10, 2026, allowing the common stock to remain listed on The Nasdaq Capital Market. Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.